GlycoMimetics

At GlycoMimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. Our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. GlycoMimetics is a clinical-stage biotechnology company. We use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. Since the company’s inception in 2003, we have developed a robust, diversified product pipeline. We are a public company traded on the NASDAQ under the symbol GLYC.
Company Growth (employees)
Type
Public
HQ
Rockville, US
Founded
2003
Size (employees)
42 (est)+11%
GlycoMimetics was founded in 2003 and is headquartered in Rockville, US

Key People at GlycoMimetics

Brian Hahn

Brian Hahn

Chief Financial Officer
John J. Baldwin

John J. Baldwin

Director
Michael Henos

Michael Henos

Director
Franklin H. Top

Franklin H. Top

Director
William Gust

William Gust

Director
M. James Barrett

M. James Barrett

Chairman of the Board of Directors

GlycoMimetics Office Locations

GlycoMimetics has an office in Rockville
Rockville, US (HQ)
9708 Medical Center Dr

GlycoMimetics Metrics

GlycoMimetics Financial Metrics

Revenue (2016)

$18.5 k

Revenue growth (2015-16), %

(100%)

Net income (2016)

($31.8 m)

Market capitalization (21-Mar-2017)

$147.7 m

Closing share price (21-Mar-2017)

$6.4
GlycoMimetics's current market capitalization is $147.7 m.
GlycoMimetics's revenue was reported to be $18.5 k in FY, 2016 which is a 99.9% decrease from the previous period.
FY, 2014FY, 2015FY, 2016

Revenue

$15 m$20.1 m$18.5 k

Revenue growth, %

34%(100%)

Operating expense total

$26.2 m$32.9 m

EBIT

($11.1 m)($12.8 m)

EBIT margin, %

(74%)(64%)

Net Income

($11.1 m)($12.8 m)($31.8 m)
FY, 2014FY, 2015

Cash From Operating Activities

$52.9 m($8.4 m)

GlycoMimetics Market Value History

GlycoMimetics Company Life

You may also be interested in